I believe Sleven gave you the best answer. I will just expand a little. I can remember even when Amarin's stock price after R-I was flying high, many here (probably including myself) were bitching that the analysts and market was not valuing the European opportunity for V correctly. We now, after these past few years, know that the market and analysts were more accurate than many of us figuring how difficult it is to break through in that market (at least for a tiny one drug company like Amarin).
I say all that to highlight that our stock price currently reflects very little of the EU opportunity and the static but ever degrading US market. The market is forward looking and values growth that it can see going forward. So ultimately to get to your question, even any excitement over any potential benefit from any positive AD results (from BRAVE-EPA) is not showing up because
a) it would be years before V could get approval and,
b) the idea is that any off-label scripts written for V (for AD) would be chewed up by the Generics no differently than the scripts written for CVD. Yes, Amarin seems to be holding US scripts somewhat steady but at the cost that they have dropped their margins to the point where on hundreds of millions of dollars of sales, they are not making any or very little profit.
But ultimately, for us investors, this is where the potential windfall lies. Like Sleven pointed out, the expectations are low currently. If Amarin can change some dynamics and start to show profits, the market will start chasing us and the stock price higher as they would be missing out. Buffett I believe said that the market is a mechanism that transfer wealth from the impatient to the patient. Let's hope that works here soon because many of us are on the verge of losing patience.
Market Data 
Markets 
AI
